Lapatinib

Type: Keyphrase
Name: Lapatinib
First reported Apr 23 2014 - Updated 12 hours ago - 6 reports

Revolutionary breast cancer drug "too expensive"

A new drug for breast cancer which extends women's lives by almost six months, and was trialled in the North East, is to be blocked from routine NHS access under draft guidance issued by a health watchdog.Kadcyla, manufactured by Roche, can cost more ... [Published itv.com - 15 hours ago]
First reported 17 hours ago - Updated 17 hours ago - 1 reports

Cost Control in the UK

Via the Guardian: A Herceptin-style drug that can offer some women with advanced breast cancer nearly six months of extra life has been turned down for use in the NHS because of its high cost. In draft guidance now open to consultation, the ... [Published Balloon Juice - 17 hours ago]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

More Drugs Added to FDA Watch List

The US Food and Drug Administration (FDA) has placed a generic drug that treats attention-deficit/hyperactivity disorder (ADHD) along with certain anticancer drugs on its latest quarterly list of products to monitor because of potential health risks, ... [Published Diabetes Care - Apr 21 2014]
First reported Apr 20 2014 - Updated Apr 21 2014 - 1 reports

Disturbing Discovery: New Generation of Targeted Cancer Drugs Cause Tumors To Become Drug Resistant and More Aggressive

In a modest-sized lab at the Moores Cancer Center at the University of California, San Diego, scientists investigating how cancer cells develop resistance to drug treatments recently discovered something that surprised even the most seasoned members of ... [Published International Business Times - Apr 20 2014]
Entities: Cancer, Drugs, Tumor, Tarceva
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

NeoALTTO Trial: For HER2-Positive Breast Cancer, pCR Leads to Increased Overall Survival

Image ToolsWomen diagnosed with breast cancer who are able to achieve a pathological complete response (pCR) to treatment with HER2-receptor antagonists appear to have significantly longer overall and event-free survival, according to a study reported ... [Published Oncology Times - Apr 18 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Science Snaps: designer drugs

They may look like pictures from a strange forest on another planet, but these illustrations depict a key process in all our cells that dictates when a cell will grow, divide or move.It’s tightly regulated, but if faults arise then cells can grow and ... [Published Cancer Research UK - Apr 18 2014]
Entities: Receptor, Tumor, Protein
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

New Biomedicine and Biomedical Engineering Study Results from Vanderbilt University Described

(NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Biotechnology have been published. According to news originating from Nashville, Tennessee, by NewsRx correspondents, research stated, "The overexpression of ... [Published NewsRX - Apr 18 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

AACR: Study identifies potential approach to overcome breast cancer resistance to HER2-targeted therapies

Resistance to a combination of HER2-targeted therapies, trastuzumab and lapatinib, was associated with elevated activation of a group of proteins called fibroblast growth factor receptors (FGFRs), which are the target of a number of drugs currently being ... [Published Ecancer Medicalscience - Apr 08 2014]
Entities: Tumor, Lapatinib, Herceptin
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Intermittent Lapatinib Hits Roadblock in HER2 Breast Cancer Study

In an attempt to fully inactivate the HER2 kinase, researchers found that intermittent oral lapatinib in patients with HER2-amplified breast cancer could be escalated up to 7,000 mg per day with no dose limiting toxicities, a treatment regimen first tested ... [Published Cancernetwork.com - Apr 08 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Letrozole–lapatinib combination did not improve outcomes in HR-positive, HER-2–negative breast cancer

The addition of lapatinib to letrozole did not significantly improve response rates in women with HR-positive, HER-2–negative operable breast cancer, according to results of a phase 2b study.However, patients with PIK3CA mutations were more likely to ... [Published Orthopedics Today - Apr 03 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

MERRIMACK PHARMACEUTICALS : "Combination Therapies Comprising Anti-Erbb3 Agents" in Patent Application Approval Process

By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors ZHANG, Bo ( Lynnfield, MA ); McDonagh, Charlotte ( Winchester, MA ); Huhalov, Alexandra ( Cambridge, MA ), filed on August 30, 2013 , was made available ... [Published 4 Traders - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Human medicines European public assessment report (EPAR): Tyverb, lapatinib, Revision: 19, Authorised

Entities: Tyverb, Lapatinib

Quotes

...His poster, entitled "Combination therapy with a MEK inhibitor plus T-type calcium channel inhibitor is highly effective in patient-derived pancreatic ductal adenocarcinomas" concludes that combination therapy with the MEK inhibitor trametinib plus Tau's T-type calcium channel inhibitor mibefradil results in significant growth...
"I hope Roche will act in the best interest of patients and use the consultation period to look again at their evidence and consider if there is more they could do."
Breakthrough Breast Cancer’s senior policy manager, Dr Caitlin Palframan, says in a statement: "The drug appraisal process in England, and the cost of drugs, must change if prospects for patients are going to improve. This is the third highly effective breast cancercancer drug to be rejected by NICE on the basis of cost in the last year and we will be responding to this latest decision, as well as the wider proposed changes to NICE’s drug appraisal process, in due course."

More Content

All (71) | News (69) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
2014 ASCO Annual Meeting Press Program to Highl... [Published American Society of Clinical Oncology - 8 hours ago]
Tau Therapeutics Collaborator Presents Data at ... [Published HispanicBusiness.com - 9 hours ago]
Revolutionary breast cancer drug "too expensive" [Published itv.com - 15 hours ago]
Cost Control in the UK [Published Balloon Juice - 17 hours ago]
Breast cancer drug 'too costly' [Published BootsWebMD - 19 hours ago]
Breast cancer drug too dear for NHS [Published Pharma Field - 21 hours ago]
NICE set to block use of 'unaffordable' new bre... [Published Nursing Times - 22 hours ago]
UK’s NICE rejects use of Roche’s Kadcyla for br... [Published Pharma Letter - 22 hours ago]
New breast cancer drug ‘unaffordable’ for NHS [Published OnMedicanet - 23 hours ago]
NICE rejects ‘costly’ cancer treatment for NHS use [Published National Health Executive - 23 hours ago]
Novartis Plans Acquisition of GSK’s Oncology Pr... [Published OncLive - Apr 23 2014]
Watchdog blocks breast cancer drug [Published Croydon Guardian - Apr 23 2014]
Breast cancer drug turned down for NHS use due ... [Published Guardian.co.uk - Apr 23 2014]
Cancer stem cells responsible for treatment res... [Published Fierce Biotech Research - Apr 22 2014]
Novartis pays $16bn for GSK's oncology portfolio [Published PMLive - Apr 22 2014]
More Drugs Added to FDA Watch List [Published Diabetes Care - Apr 21 2014]
Cancer Stem Cells Responsible For Disease's Res... [Published Medical Daily - Apr 21 2014]
Researchers Discover Biomarker... [Published Red Orbit - Apr 21 2014]
Disturbing Discovery: New Generation of Targete... [Published International Business Times - Apr 20 2014]
Cancer stem cells linked to drug resistance [Published Medical Xpress - Apr 20 2014]
NeoALTTO Trial: For HER2-Positive Breast Cancer... [Published Oncology Times - Apr 18 2014]
Science Snaps: designer drugs [Published Cancer Research UK - Apr 18 2014]
New Biomedicine and Biomedical Engineering Stud... [Published NewsRX - Apr 18 2014]
HER2 Targeting in Early Breast Cancer: More Opt... [Published Cancernetwork.com - Apr 17 2014]
Deep Targeted Sequencing for Breast Cancer Care [Published General Medicine eJournal - Apr 15 2014]
Tau Therapeutics, LLC Collaborator Presents Dat... [Published BioSpace - Apr 11 2014]
Tau Therapeutics Collaborator Presents Data at ... [Published BioPortfolio - Apr 11 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
AACR: Study identifies potential approach to ov... [Published Ecancer Medicalscience - Apr 08 2014]
AACR Study identifies potential approach to ove... [Published BioPortfolio - Apr 08 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cost Control in the UK [Published Balloon Juice - 17 hours ago]
Via the Guardian: A Herceptin-style drug that can offer some women with advanced breast cancer nearly six months of extra life has been turned down for use in the NHS because of its high cost. In draft guidance now open to consultation, the ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Apr 01 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.